These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31020691)

  • 1. Long term outcome of patients treated on clinical trials of immunomodulatory agents for the treatment of Immunoglobulin light chain (AL) amyloidosis: A pooled analysis.
    Sanchorawala V; Doros G; Shelton AC
    Am J Hematol; 2019 Jul; 94(7):E194-E196. PubMed ID: 31020691
    [No Abstract]   [Full Text] [Related]  

  • 2. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
    Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
    Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib.
    Ravichandran S; Cohen OC; Law S; Foard D; Fontana M; Martinez-Naharro A; Whelan C; Gillmore JD; Lachmann HJ; Sachchithanantham S; Mahmood S; Hawkins PN; Wechalekar AD
    Blood Cancer J; 2021 Jun; 11(6):118. PubMed ID: 34155191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.
    Manwani R; Cohen O; Sharpley F; Mahmood S; Sachchithanantham S; Foard D; Lachmann HJ; Quarta C; Fontana M; Gillmore JD; Whelan C; Hawkins PN; Wechalekar AD
    Blood; 2019 Dec; 134(25):2271-2280. PubMed ID: 31578202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency.
    Wu X; Miao HL; Zhu TN; Feng J; Zhang L; Mao YY; Zhou DB; Cao XX; Li J
    Amyloid; 2019 Dec; 26(4):255-256. PubMed ID: 31526149
    [No Abstract]   [Full Text] [Related]  

  • 6. Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study.
    Shen KN; Zhang CL; Tian Z; Feng J; Wang YN; Sun J; Zhang L; Cao XX; Zhou DB; Li J
    Amyloid; 2019 Jun; 26(2):66-73. PubMed ID: 31074308
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival.
    Muchtar E; Dispenzieri A; Kumar SK; Buadi FK; Lacy MQ; Zeldenrust S; Hayman SR; Leung N; Kourelis TV; Gonsalves W; Chakraborty R; Russell S; Dingli D; Lust JA; Lin Y; Kapoor P; Go R; Kyle RA; Rajkumar SV; Gertz MA
    Amyloid; 2017 Mar; 24(sup1):40-41. PubMed ID: 28434371
    [No Abstract]   [Full Text] [Related]  

  • 8. Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis.
    Kastritis E; Fotiou D; Theodorakakou F; Dialoupi I; Migkou M; Roussou M; Karatrasoglou EA; Tselegkidi MI; Ntalianis A; Kanellias N; Eleutherakis-Papaiakovou E; Ntanasis-Stathopoulos I; Gakiopoulou C; Papanikolaou A; Papathoma A; Spyropoulou-Vlachou M; Psimenou E; Stamatelopoulos K; Gavriatopoulou M; Terpos E; Dimopoulos MA
    Amyloid; 2021 Mar; 28(1):3-11. PubMed ID: 32713209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine.
    Manwani R; Sachchithanantham S; Mahmood S; Foard D; Sharpley F; Rezk T; Lane T; Quarta C; Fontana M; Lachmann HJ; Gillmore JD; Whelan C; Hawkins PN; Wechalekar AD
    Blood; 2018 Aug; 132(7):761-764. PubMed ID: 29925500
    [No Abstract]   [Full Text] [Related]  

  • 10. Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis.
    Lentzsch S; Lagos GG; Comenzo RL; Zonder JA; Pregja S; Osman K; Tsai WY; Landau H; Sanchorawala V
    Amyloid; 2019; 26(sup1):113-114. PubMed ID: 31343313
    [No Abstract]   [Full Text] [Related]  

  • 11. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis.
    Wechalekar AD; Whelan C
    Blood Cancer J; 2017 Mar; 7(3):e546. PubMed ID: 28338670
    [No Abstract]   [Full Text] [Related]  

  • 12. Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016.
    Rutten KHG; Raymakers RAP; Hazenberg BPC; Nienhuis HLA; Vellenga E; Minnema MC
    Amyloid; 2018 Dec; 25(4):227-233. PubMed ID: 30513220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.
    Qiu Y; Zhang CL; Shen KN; Su W; Feng J; Zhang L; Cao XX; Li J
    Ann Hematol; 2018 Dec; 97(12):2465-2470. PubMed ID: 30056579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy.
    Wong SW; Larivee D; Warner M; Sprague KA; Fogaren T; Comenzo RL
    Bone Marrow Transplant; 2017 Jun; 52(6):936-937. PubMed ID: 28394371
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of systemic AL amyloidosis: about 25 cases].
    Eddou H; Zinebi A; Maaroufi HE; Moudden MK; Doghmi K; Mikdame M; Baaj ME
    Pan Afr Med J; 2017; 28():160. PubMed ID: 29541306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data.
    Ravichandran S; Cohen OC; Law S; Sachchithanantham S; Mahmood S; Foard D; Fontana M; Martinez-Naharro A; Whelan C; Gillmore JD; Lachmann HJ; Hawkins PN; Wechalekar AD
    Br J Haematol; 2021 Aug; 194(3):587-597. PubMed ID: 34189728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factoring in the missing link.
    Sethi N; Sedighi Manesh R; Sperling A; Bresler SC; Connell NT; Tierney LM
    Am J Hematol; 2017 Jan; 92(1):110-113. PubMed ID: 27486087
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination of bortezomib in the induction, conditioning and consolidation with autologous hematopoietic stem cell transplantation in patients with immunoglobulin light chain amyloidosis.
    Huang X; Fu C; Chen L; Chen W; Ren G; Guo J; Zhao L; Zeng C; Zhang H; Gong D; Ren Q; Liu Z
    Am J Hematol; 2019 Apr; 94(4):E101-E104. PubMed ID: 30652338
    [No Abstract]   [Full Text] [Related]  

  • 19. Bortezomib therapy-related lung disease in a patient with light chain amyloidosis: A case report.
    Balsman E
    J Oncol Pharm Pract; 2017 Oct; 23(7):545-548. PubMed ID: 27357815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis.
    Sharpley FA; Manwani R; Mahmood S; Sachchithanantham S; Lachmann H; Gilmore J; Whelan C; Hawkins P; Wechalekar A
    Br J Haematol; 2018 Nov; 183(4):557-563. PubMed ID: 30095161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.